ライフサイエンスコーパス: acute heart failure

1 lly the need to improve clinical outcomes in acute heart failure.

2 use in the broad population of patients with acute heart failure.

3 0.674 vs. 0.606, respectively, p < 0.001) in acute heart failure.

4 for early relief of dyspnea in patients with acute heart failure.

5 se outcomes, often develops in patients with acute heart failure.

6 e favorable clinical course in patients with acute heart failure.

7 e of hemodynamic monitoring in patients with acute heart failure.

8 ezosentan improves outcomes in patients with acute heart failure.

9 f which is systemic iron overload leading to acute heart failure.

10 mptoms or clinical outcomes in patients with acute heart failure.

11 ical effects of tezosentan in the setting of acute heart failure.

12 rmone that has been studied in patients with acute heart failure.

13 s of rolofylline to placebo in patients with acute heart failure.

14 nce of decongestive therapy in patients with acute heart failure.

15 as been associated with improved survival in acute heart failure.

16 n chronic heart failure and of new drugs for acute heart failure.

17 severe risk would improve the management of acute heart failure.

18 Serelaxin is a promising therapy for acute heart failure.

19 e and placebo in 2033 patients admitted with acute heart failure.

20 ed diagnostic and therapeutic strategies for acute heart failure.

21 ischemic ECG abnormalities in patients with acute heart failure.

22 cal trial data has shown benefit in treating acute heart failure.

23 e them to 180-day mortality in patients with acute heart failure.

24 y reduce 30-day recidivism for patients with acute heart failure.

25 siderosis but none relating to treatment of acute heart failure.

26 y measures, and designing clinical trials in acute heart failure.

27 ve clinical outcome signals in patients with acute heart failure.

28 axin is showing potential as a treatment for acute heart failure.

29 ase III clinical trials for the treatment of acute heart failure.

30 Acute heart failure accounted for 2.2% (range: 0.3%-7.7%

31 igated a wide range of biomarker profiles in acute heart failure across the body mass index (BMI) spe

32 in, an emerging pharmaceutical treatment for acute heart failure, activates the relaxin family peptid

33 ohort of patients discharged from a previous acute heart failure admission.

34 d additional tools to stratify patients with acute heart failure (AHF) according to risk.

35 ing renal function (WRF) often occurs during acute heart failure (AHF) and can portend adverse outcom

36 g/dL, is a frequent finding in patients with acute heart failure (AHF) and has been associated with p

37 tic peptide (MR-proANP) for the diagnosis of acute heart failure (AHF) and the prognostic value of mi

38 lth literacy to recidivism for patients with acute heart failure (AHF) are not known.

39 Little is known about mode of death after acute heart failure (AHF) hospitalization.

40 differentiation of ischemic and nonischemic acute heart failure (AHF) in the emergency department (E

41 nischemic origin in patients presenting with acute heart failure (AHF) not resulting from acute myoca

42 We report 5 cases of acute heart failure (AHF) related to multiple sclerosis

43 d 1161 patients admitted to the hospital for acute heart failure (AHF) to evaluate the therapeutic ef

44 iratory flow rate (PEFR) would increase with acute heart failure (AHF) treatment over the first 24 h,

45 nsitional care intervention in patients with acute heart failure (AHF) who are discharged either dire

46 In patients with acute heart failure (AHF), dyspnea relief is the most im

47 gestion is associated with worse outcomes in acute heart failure (AHF).

48 proving the clinical course of patients with acute heart failure (AHF).

49 safety, and efficacy of OM in patients with acute heart failure (AHF).

50 ets, and hypochloremia predicts mortality in acute heart failure (AHF).

51 reason for hospitalization in patients with acute heart failure (AHF).

52 levated blood glucose level and mortality in acute heart failure (AHF).

53 rain natriuretic peptide in the diagnosis of acute heart failure and for improved clinical outcomes w

54 ization should be reserved for patients with acute heart failure and impending respiratory or circula

55 gement continuum of patients presenting with acute heart failure and included heart failure cardiolog

56 When given to patients with acute heart failure and normal-to-increased blood pressu

57 on [ROSE]) of 360 hospitalized patients with acute heart failure and renal dysfunction (estimated glo

58 Patients with acute heart failure and renal dysfunction demonstrate va

59 ries of renal function in 1962 patients with acute heart failure and renal dysfunction enrolled in th

60 In participants with acute heart failure and renal dysfunction, neither low-d

61 and preserve renal function in patients with acute heart failure and renal dysfunction; however, neit

62 grated delivery system who visited an ED for acute heart failure and were discharged from January 1,

63 y, 4 patients had atrial fibrillation, 1 had acute heart failure, and 1 had incidental disease at aut

64 rs for chronic heart failure, nesiritide for acute heart failure, and cytochrome P-450 (CYP) 2C19 gen

65 a multitude of causes, including arrhythmia, acute heart failure, and myocardial infarction.

66 , race, and sex as well as trends of sepsis, acute heart failure, and receipt of cardiac catheterizat

67 primary driver of symptoms in patients with acute heart failure, and relief of congestion is a criti

68 Interventions to improve management of acute heart failure are required at low-volume sites.

69 camtiv Mecarbil to Increase Contractility in Acute Heart Failure [ATOMIC-AHF]; NCT01300013).

70 (Biomarkers in Acute Heart Failure [BACH]; NCT00537628).

71 (Biomarkers in Acute Heart Failure [BACH]; NCT00537628).

72 ith baseline and worsening renal function in acute heart failure, but none has modeled the trajectori

73 ave been the mainstay of medical therapy for acute heart failure, but, in recent years, there has bee

74 generating capability and, in the setting of acute heart failure, can increase CO and mean arterial p

75 om any cardiac cause, myocardial infarction, acute heart failure, cardiac arrest, arrhythmia, complet

76 relations among end points typical in recent acute heart failure clinical trials were used.

77 Under acute heart failure conditions, both SMV and IABP assist

78 Admissions for acute heart failure continue to increase but, to date, n

79 e heart failure patients, such as those with acute heart failure decompensation in the setting of cli

80 ied version of the risk-prediction model for acute heart failure developed from patients in the EFFEC

81 Patients enrolled in a large RCT of acute heart failure differed significantly based on clin

82 diuretic optimization strategy evaluation in acute heart failure (DOSE-AHF), enrolling patients hospi

83 group, dose-ranging study, 234 patients with acute heart failure, dyspnoea, congestion on chest radio

84 In patients with acute heart failure, early intervention with an intraven

85 (Renal Optimization Strategies Evaluation in Acute Heart Failure) found that when compared with place

86 Acute heart failure has become a major medical issue in

87 Many patients with acute heart failure have marked hypertension and preserv

88 Most patients admitted for acute heart failure have normal or increase blood pressu

89 Cardiorenal syndrome is common in acute heart failure (HF) and portends poor prognosis.

90 Hospitalization for acute heart failure (HF) is associated with high rates o

91 We used data from 2 acute heart failure (HF) trials from the National Instit

92 It is unclear how patients hospitalized for acute heart failure (HF) who are long-term chronic HF su

93 transplantation, 10 unused donor hearts with acute heart failure (HF), 37 patients with chronic HF, a

94 receptor family member ST2 in patients with acute heart failure (HF).

95 tor antagonist, in patients hospitalized for acute heart failure (HF).

96 redict rehospitalization after admission for acute heart failure (HF).

97 included those with a principal diagnosis of acute heart failure (ICD-9-CM 402 and 428; ICD-10 I50.x,

98 ed risk of 30-day mortality in patients with acute heart failure, identifying both high- and low-risk

99 ion (MI) in 2.9%, post MI in 20.6%, shock or acute heart failure in 3.0% and restenosis in 19.1%.

100 atory (embolic or aneurysm rupture) in 7 and acute heart failure in 4.

101 Acute heart failure in adults is the unfolding of heart

102 AMPD1 gene appears to be protective against acute heart failure in cardiac donors.

103 One of the lung edema dogs expired of acute heart failure in the seventh hour of the experimen

104 Acute heart failure is a common reason for admission, an

105 Hospitalization for acute heart failure is associated with high post-dischar

106 The first principle of management of acute heart failure is control of cardiac toxicity relat

107 The cause of this acute heart failure is poorly understood.

108 The prognosis of acute heart failure is such that many children are consi

109 Acute heart failure is unusual in the pediatric populati

110 studies are warranted to better characterize acute heart failure management with UF in this populatio

111 apabilities to diagnose and prognosticate in acute heart failure, natriuretic peptides are now being

112 Acute heart failure occurred in 5 patients: 3 underwent

113 50 patients hospitalised with acute heart failure or acute coronary syndrome and with

114 e myocardial infarction (AMI) complicated by acute heart failure or cardiogenic shock have high morta

115 or therapeutic dilemma or when encountering acute heart failure or hemodynamic lability refractory t

116 effective strategy for patients with AMI and acute heart failure or shock in whom medical therapy is

117 expertise and target various features of the acute heart failure patient, such as circulatory failure

118 arying site enrollment volume among all 7141 acute heart failure patients from the ASCEND-HF trial (A

119 ropes may be a necessary evil in a subset of acute heart failure patients, such as those with acute h

120 actice patterns, and in-hospital outcomes of acute heart failure patients.

121 The Pre-RELAX-AHF (Relaxin in Acute Heart Failure) phase II study and RELAX-AHF phase

122 ables measured on admission in patients with acute heart failure predict a variety of adverse outcome

123 defects of the myocardium may predispose to acute heart failure presenting as AM, notably after comm

124 rimination in a broad group of patients with acute heart failure presenting to the ED.

125 study, which enrolled patients admitted with acute heart failure, regardless of ejection fraction or

126 The Relaxin for the Treatment of Acute Heart Failure (RELAX-AHF) trial enrolled 1161 pati

127 Acute heart failure resulting from cardiomyopathy has si

128 helin Receptor Inhibition With Tezosentan in Acute Heart Failure Studies, 2 independent, identical, a

129 using global statistical methods in phase II acute heart failure studies.

130 The recently published BACH (Biomarkers in Acute Heart Failure) study demonstrated that MR-proADM h

131 y and Safety of Relaxin for the Treatment of Acute Heart Failure) study, serelaxin, the recombinant f

132 Myocarditis is an underdiagnosed cause of acute heart failure, sudden death, and chronic dilated c

133 Patients who present with acute heart failure suffer from a severe complication of

134 Although most research on patients with acute heart failure syndrome (AHFS) has focused on readm

135 nities of emergency department management of acute heart failure syndrome (AHFS).

136 cardiomyopathy is an increasingly recognized acute heart failure syndrome precipitated by intense emo

137 This condition represents an acute heart failure syndrome with substantial morbidity

138 asurements, in patients hospitalized with an acute heart failure syndrome.

139 Acute heart failure syndromes (AHFS) have emerged as a l

140 d regional differences in clinical trials of acute heart failure syndromes (AHFS) have not been well

141 Acute heart failure syndromes (AHFS) remain a major caus

142 Acute heart failure syndromes (AHFS), with a high post-d

143 ns (cTn) may be elevated among patients with acute heart failure syndromes (AHFS).

144 Although acute heart failure syndromes are commonly defined as a

145 In patients with acute heart failure syndromes, a simple assessment of PV

146 gle most important goal in the management of acute heart failure syndromes.

147 an 78 years [Q1, Q3: 68,84]) presenting with acute heart failure to 86 hospital emergency departments

148 g the holy grail of evaluating patients with acute heart failure to being all but extinct.

149 ial, we randomly assigned 2157 patients with acute heart failure to receive a continuous intravenous

150 ned 7141 patients who were hospitalized with acute heart failure to receive either nesiritide or plac

151 ariables, measured at hospital admission for acute heart failure, to determine whether a few selected

152 laxin should be pursued in larger studies of acute heart failure, to identify an optimum dose, and to

153 mber of participants enrolled per site in an acute heart failure trial is associated with participant

154 In this large, acute heart failure trial, site enrollment correlated wi

155 The BACH (Biomarkers in Acute Heart Failure) trial was a prospective, 15-center,

156 Most international acute heart failure trials have failed to show benefit w

157 llenges to be considered in design of future acute heart failure trials.

158 In patients with acute heart failure, ularitide exerted favorable physiol

159 ventricular ejection fraction</=35%) died of acute heart failure unrelated to ventricular arrhythmias

160 patients with chronic heart failure or mild acute heart failure, use of the reduction in pulmonary a

161 Acute heart failure was induced in 6 of the pigs by snar

162 rehospitalization due to cardiac reasons and acute heart failure was similar in both groups at 1 year

163 models of diffuse myocardial damage causing acute heart failure, we show that eCSCs restore cardiac

164 ed trials in which patients hospitalized for acute heart failure were randomized within 16 h to intra

165 A cohort of patients with acute heart failure who presented to 4 emergency departm

166 enrolling patients admitted to hospital for acute heart failure who were randomly assigned (1:1) via

167 ed trial involving patients hospitalized for acute heart failure with impaired renal function.

168 It does not show promise in the treatment of acute heart failure with renal dysfunction.

169 Treatment of acute heart failure with serelaxin was associated with d

170 INTERPRETATION: Treatment of acute heart failure with serelaxin was associated with d

171 gly, these embryos die in mid-gestation from acute heart failure, with reduced proliferation of ventr

172 A third animal died of acute heart failure within 2 minutes of seizure onset, a